Provided by Tiger Trade Technology Pte. Ltd.

InMed Pharmaceuticals Inc

1.46
-0.1200-7.59%
Post-market: 1.460.00000.00%17:48 EDT
Volume:71.61K
Turnover:107.41K
Market Cap:7.80M
PE:-0.58
High:1.62
Open:1.58
Low:1.45
Close:1.58
52wk High:2.50
52wk Low:0.5750
Shares:5.34M
Float Shares:1.93M
Volume Ratio:0.67
T/O Rate:3.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5324
EPS(LYR):-8.3630
ROE:-112.65%
ROA:-54.61%
PB:1.13
PE(LYR):-0.17

Loading ...

Mentari Therapeutics Merger with Inmed Set to Close Ahead of USD 200 Million Private Placement

Reuters
·
Jul 22

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

THOMSON REUTERS
·
Jul 22

ADAR1 Capital Acquires 1,000 Inmed Common Shares Worth $1,555

Reuters
·
Jul 18

Vivo Opportunity Reports USD 32,319 Purchase of Inmed Common Shares

Reuters
·
Jul 17

Inmed Amends Merger Deal with Mentari, Files S-4 Registration Statement

Reuters
·
Jul 11

InMed Pharmaceuticals amends merger pact with Mentari Therapeutics

TIPRANKS
·
Jul 07

Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares

Reuters
·
Jul 03

Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares

Reuters
·
Jun 11

InMed Pharmaceuticals files Form 3 as Vivo Opportunity discloses beneficial ownership of 541,752 shares

Reuters
·
Jun 11

InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule

Reuters
·
Jun 10

InMed regains compliance with Nasdaq continued listing requirements

TIPRANKS
·
Jun 05

InMed Pharma releases INM-089 age-related macular degeneration presentation

Reuters
·
Jun 03

ADAR1 Capital Management acquires 468,551 InMed common shares worth $742,290

Reuters
·
May 22

InMed Pharmaceuticals files Form 3 showing ADAR1 Capital Management stake of 331,449 shares

Reuters
·
May 22

BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy

Reuters
·
May 19

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM

Reuters
·
May 19

InMed Pharmaceuticals agrees to all-stock merger with Mentari Therapeutics

Reuters
·
May 19

InMed Pharmaceuticals: InMed Shareholders Are Expected to Own Approximately 1.51% of Combined Company

THOMSON REUTERS
·
May 19

InMed Pharmaceuticals: Post Deal, Combined Company to Have Pro Forma Equity Value of About US$421.4 Mln (Inclusive of Private Placement)

THOMSON REUTERS
·
May 19

Press Release: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Dow Jones
·
May 19